E. Bartok

hnRNPM and ELAVL1 control type I interferon induction by promoting IRF3 phosphorylation downstream of both cGAS and RIG-I

RIG-I activation primes and trains innate antiviral immune memory

RIG-I activation primes and trains innate immune responses, enhancing non-specific antiviral protection in immune and non-immune cells.

A conserved isoleucine in the binding pocket of RIG-I controls immune tolerance to mitochondrial RNA

This study identifies an isoleucine residue in RIG-I that prevents recognition of 5p-RNA, thereby maintaining immune tolerance to mitochondrial RNA.

Monocyte-derived macrophages aggravate pulmonary vasculitis via cGAS/STING/IFN-mediated nucleic acid sensing

This study identifies cGAS/STING/IFN-mediated nucleic acid sensing by monocyte-derived macrophages as a driver of severe pulmonary vasculitis and shows that targeting this pathway reduces disease severity.

Revisiting the origin of interleukin 1 (IL-1) based on biological activities of IL-1 in anamniotes and their sub-functionalization in amniotes

The paper investigates the evolutionary origin of IL-1 by comparing its biological activities in anamniotes and amniotes, finding sub-functionalization in mammals.

RIG-I immunotherapy overcomes radioresistance in p53-positive malignant melanoma

This study shows that RIG-I ligands enhance radiation-induced tumor cell death and immunogenicity in melanoma, with p53 playing a key role in the synergy between RIG-I and radiation.

RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection

This study shows that activating the RIG-I receptor with synthetic RNA oligonucleotides before SARS-CoV-2 infection improves mouse survival and reduces viral load.

ADA2 is a lysosomal DNase regulating the type-I interferon response

The paper identifies ADA2 as a lysosomal DNase that regulates the type-I interferon response by degrading cGAS/Sting-activating ligands in DADA2 patients.